Does Blue Cross Blue Shield of Minnesota Cover Trulicity?

How BCBS MN Classifies Trulicity on Its Formulary

Blue Cross Blue Shield of Minnesota places Trulicity (dulaglutide) on its prescription drug formulary for most commercial, individual, and Medicare Advantage plans. The specific tier varies by plan year and product line. In the 2025-2026 formulary updates, BCBS MN lists Trulicity as a tier 3 preferred brand medication on most commercial PPO and HMO plans, while some Medicare Advantage plans classify it as tier 4 (non-preferred brand) 1.

Tier placement matters because it directly determines your out-of-pocket cost. A tier 3 drug on a BCBS MN commercial plan typically carries a copay between $50 and $100 per fill. Tier 4 placement pushes that range to $100 to $150, and some high-deductible health plans (HDHPs) require you to meet your full deductible before any copay applies. Your plan's Summary of Benefits and Coverage document, available through the BCBS MN member portal, will show the exact tier 2.

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists like dulaglutide as a second-line agent after metformin for patients with type 2 diabetes, particularly those with established cardiovascular disease or high cardiovascular risk 2. This guideline alignment is one reason BCBS MN maintains formulary coverage rather than excluding the drug outright.

Prior Authorization Requirements for Trulicity

Almost every BCBS MN plan requires prior authorization (PA) before a pharmacy can dispense Trulicity. This is standard practice across most commercial insurers for branded GLP-1 receptor agonists. The PA process verifies that the prescribing physician has documented a clinical need that meets BCBS MN's medical policy criteria 3.

BCBS MN's PA criteria for Trulicity generally require three things. First, a confirmed diagnosis of type 2 diabetes mellitus with an HbA1c at or above 7.0%. Second, documentation that the patient has tried and either failed or cannot tolerate metformin at a dose of at least 1 to 500 mg daily for a minimum of 90 days. Third, the prescriber must confirm the medication is not being used solely for weight management.

Your prescriber's office submits the PA request electronically or by fax. BCBS MN typically responds within 48 to 72 hours for standard requests and within 24 hours for urgent requests. If the PA is approved, coverage is usually authorized for 12 months before a renewal review 4.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has stated: "Prior authorization requirements for GLP-1 receptor agonists create unnecessary barriers for patients with type 2 diabetes who have clear clinical indications for these medications" 2. That sentiment reflects a growing push from professional organizations to reduce PA burdens for guideline-supported therapies.

Step Therapy: What You Must Try First

Step therapy is the mechanism BCBS MN uses to require cheaper medications before approving a branded agent like Trulicity. For type 2 diabetes coverage, the typical step therapy sequence starts with metformin.

Here is how the step therapy ladder usually works on BCBS MN plans:

Step 1: Metformin (generic, tier 1). Your prescriber must document a trial of at least 90 days at therapeutic doses. If your HbA1c remains above target (typically 7.0% or above), you advance to step 2.

Step 2: A sulfonylurea (glipizide or glimepiride) or an SGLT2 inhibitor may be required as a second trial on some plans. Not all BCBS MN plans enforce this second step for GLP-1 access. Check your plan's drug policy document.

Step 3: GLP-1 receptor agonists, including Trulicity, become available once prior steps are documented as insufficient.

The AWARD-7 trial (N=577) demonstrated that dulaglutide 1.5 mg reduced HbA1c by 1.28 percentage points compared to 0.99 points with insulin glargine over 52 weeks in patients with moderate-to-severe chronic kidney disease 5. Data like this supports the clinical rationale for advancing patients through step therapy to reach a GLP-1 agent when earlier treatments fall short.

One exception to step therapy: patients with documented cardiovascular disease or multiple cardiovascular risk factors may qualify for an expedited pathway. The REWIND trial (N=9,901) showed that dulaglutide 1.5 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 12% (HR 0.88 to 95% CI 0.79-0.99, P=0.026) over a median 5.4 years of follow-up 3. BCBS MN's medical policy recognizes this cardiovascular benefit, and prescribers can cite it to bypass or shorten the step therapy process for high-risk patients.

What Trulicity Costs with BCBS MN Insurance

Out-of-pocket costs for Trulicity under a BCBS MN plan depend on your formulary tier, plan type, and whether you have met your deductible. Here are realistic estimates based on common BCBS MN plan designs 6:

| Plan Type | Likely Tier | Estimated Monthly Copay | |-----------|-------------|------------------------| | Commercial PPO | Tier 3 (preferred brand) | $50 to $100 | | Commercial HMO | Tier 3 (preferred brand) | $40 to $80 | | HDHP before deductible met | Full cost applies | $950 to $1,100 | | HDHP after deductible met | Coinsurance (20%-30%) | $190 to $330 | | Medicare Advantage | Tier 4 (non-preferred brand) | $80 to $150 | | Medicare Part D (coverage gap) | 25% coinsurance | ~$250 |

Without any insurance, Trulicity's retail price runs approximately $950 to $1,100 for a 30-day supply (four weekly pens of 1.5 mg) at most Minnesota pharmacies. Eli Lilly's Trulicity Savings Card can reduce the copay to as little as $25 per month for commercially insured patients who meet eligibility criteria. This card does not apply to government-funded insurance programs like Medicare, Medicaid, or Tricare 6.

For Medicare Part D enrollees who enter the coverage gap (the "donut hole"), manufacturer discounts and the federal subsidy combine to cap your out-of-pocket share at 25% of the drug's negotiated price. Once your total out-of-pocket spending reaches $8 to 000 in 2025 (under the Inflation Reduction Act cap), catastrophic coverage begins and your costs drop to $0 for the remainder of the plan year 7.

What to Do If BCBS MN Denies Your Trulicity Claim

Denials happen. The most common reasons BCBS MN denies a Trulicity prior authorization are incomplete documentation, failure to demonstrate step therapy compliance, or an HbA1c that does not meet the policy threshold. A denial is not a final answer.

Step 1: Read the denial letter carefully. BCBS MN is required to provide a specific reason for the denial and cite the medical policy criteria you did not meet. This letter also includes your appeal rights and deadlines.

Step 2: Request a peer-to-peer review. Your prescribing physician can call BCBS MN and speak directly with the reviewing medical director. Peer-to-peer reviews resolve many denials within a single phone call because the prescriber can provide clinical context that was missing from the initial PA submission 8.

Step 3: File a formal internal appeal. You have 180 days from the denial date to submit an internal appeal to BCBS MN. Include updated lab results (HbA1c, fasting glucose), a letter of medical necessity from your prescriber, documentation of all prior medication trials, and any relevant clinical trial data supporting GLP-1 use for your specific situation. The SUSTAIN-6 trial (N=3,297) and REWIND trial (N=9,901) both established cardiovascular and glycemic benefits of GLP-1 receptor agonists that support medical necessity arguments 3 9.

Step 4: External review. If the internal appeal fails, Minnesota state law gives you the right to request an external review by an independent review organization (IRO). The Minnesota Department of Commerce oversees this process. External reviews are binding on the insurer.

The 2023 AMA Prior Authorization Physician Survey found that 94% of physicians reported care delays due to prior authorization, and 33% reported that PA led to a serious adverse event for a patient 10. If your treatment is being delayed, document every interaction and escalate promptly.

Trulicity Alternatives Covered by BCBS MN

If Trulicity is denied or placed on a non-preferred tier that makes it too expensive, BCBS MN covers several alternative GLP-1 receptor agonists. Your prescriber may recommend switching to a preferred formulary option.

Ozempic (semaglutide): Often on the same formulary tier as Trulicity or occasionally preferred. The SUSTAIN-7 trial (N=1,201) showed semaglutide 1.0 mg achieved a 1.8 percentage-point HbA1c reduction compared to 1.4 points with dulaglutide 1.5 mg at 40 weeks, with semaglutide also producing greater weight loss (6.5 kg vs. 3.0 kg) 11. If BCBS MN prefers semaglutide, this switch may lower your copay while providing comparable or superior glycemic control.

Mounjaro (tirzepatide): A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes. The SURPASS-2 trial (N=1,879) demonstrated that tirzepatide 15 mg reduced HbA1c by 2.58 percentage points versus 1.86 points with semaglutide 1 mg 12. Formulary placement for Mounjaro varies significantly across BCBS MN plans.

Victoza (liraglutide): An older GLP-1 option. It requires daily injections rather than Trulicity's weekly dosing. Some plans list liraglutide at a lower tier due to its longer market history and established safety profile from the LEADER trial (N=9,340), which showed a 13% reduction in major cardiovascular events 13.

Rybelsus (oral semaglutide): The only oral GLP-1 receptor agonist. PIONEER-4 (N=711) showed oral semaglutide 14 mg produced non-inferior HbA1c reductions compared to subcutaneous liraglutide 1.8 mg 14. Some patients prefer this option to avoid injections entirely.

The Endocrine Society's 2023 clinical practice guideline on pharmacologic management of type 2 diabetes notes: "GLP-1 receptor agonists with proven cardiovascular benefit should be prioritized in patients with established atherosclerotic cardiovascular disease, regardless of HbA1c level" 15. This guideline language can support appeals for any GLP-1 agent on the BCBS MN formulary.

How to Verify Your Specific BCBS MN Coverage

Formulary details change annually, and individual BCBS MN plans within the same product line can differ. Do not rely solely on general guidance. Verify your specific coverage through these channels.

Member portal: Log in to bluecrossmn.com and manage to the "Pharmacy" or "Drug Coverage" section. Enter "Trulicity" or "dulaglutide" in the formulary search tool to see your plan's tier, PA requirements, and quantity limits.

Call member services: The number on the back of your BCBS MN card connects you to a representative who can confirm coverage, tier, estimated copay, and whether PA has already been initiated by your prescriber.

Ask your pharmacy: Your pharmacist can run a real-time benefits check (RTBC) to see whether your BCBS MN plan will cover Trulicity at the point of sale and what your copay would be before filling the prescription 2.

Request a formulary exception. If Trulicity is not on your plan's formulary or is placed on a high tier, you and your prescriber can submit a formulary exception request. This asks BCBS MN to cover Trulicity at a lower tier based on individual medical necessity. Success rates improve when the request includes documentation of failed alternatives and supporting clinical evidence.

Minnesota law requires health plans to process formulary exception requests within 72 hours for standard requests and 24 hours for urgent (expedited) requests. If you have been stable on Trulicity and are changing BCBS MN plans during open enrollment, submit a continuity of care request before your new plan's effective date to avoid a gap in medication access.